Contraindications: Not indicated for pre-menopausal women or individuals with hypersensitivity to anastrozole or any tablet excipient. Avoid use where baseline estradiol is already below the lower physiological limit (typically < 10 pg/mL by LC-MS/MS assay), as further suppression risks symptomatic estrogen deficiency.
Side Effects: Musculoskeletal stiffness and joint discomfort are among the most commonly reported effects, particularly at the 1 mg once-daily dose; splitting to AM/PM dosing may reduce peak-concentration-related joint symptoms. Mood changes, reduced libido, and fatigue can occur if estradiol is over-suppressed. Hot flashes are possible. Report persistent symptoms to a healthcare provider.
Monitoring: Confirm estradiol (E2) and total testosterone via validated serum assay at the four-week PCT checkpoint. Target estradiol range during active anastrozole PCT: 20–30 pg/mL by LC-MS/MS. LH and FSH recovery should be tracked at the same interval. Dose or timing adjustments should be data-driven rather than symptom-driven alone.
PCT: Anastrozole does not replace SERM therapy; it operates upstream by reducing circulating estradiol rather than blocking the pituitary receptor. In standard PCT frameworks, anastrozole and SERM agents are typically administered sequentially rather than simultaneously to avoid known pharmacokinetic interactions. Do not extend use beyond the period of demonstrable estradiol elevation.